Title : 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma.

Pub. Date : 2020 Oct

PMID : 32245896






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The next generation beta-particle emitting radioimmunoconjugate 177Lu-lilotomab-satetraxetan (Betalutin ) was shown to up-regulate CD20 expression in different rituximab-sensitive NHL cell lines and to act synergistically with rituximab in a rituximab-sensitive NHL animal model. 177lu-lilotomab-satetraxetan keratin 20 Homo sapiens